GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Cyclically Adjusted Revenue per Share

Biocon (NSE:BIOCON) Cyclically Adjusted Revenue per Share : ₹66.36 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Biocon Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biocon's adjusted revenue per share for the three months ended in Mar. 2024 was ₹32.248. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹66.36 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biocon's average Cyclically Adjusted Revenue Growth Rate was 18.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biocon was 16.10% per year. The lowest was 13.60% per year. And the median was 14.85% per year.

As of today (2024-06-06), Biocon's current stock price is ₹305.25. Biocon's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹66.36. Biocon's Cyclically Adjusted PS Ratio of today is 4.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biocon was 11.77. The lowest was 3.62. And the median was 7.25.


Biocon Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biocon's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Cyclically Adjusted Revenue per Share Chart

Biocon Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.24 42.41 47.70 56.01 66.36

Biocon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.01 59.18 61.54 64.05 66.36

Competitive Comparison of Biocon's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Biocon's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biocon's Cyclically Adjusted PS Ratio falls into.



Biocon Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biocon's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=32.248/153.0345*153.0345
=32.248

Current CPI (Mar. 2024) = 153.0345.

Biocon Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 6.054 94.103 9.845
201409 6.269 96.780 9.913
201412 6.363 96.780 10.062
201503 6.555 97.163 10.324
201506 6.423 99.841 9.845
201509 6.603 101.753 9.931
201512 6.695 102.901 9.957
201603 7.930 102.518 11.838
201606 8.314 105.961 12.008
201609 7.962 105.961 11.499
201612 8.722 105.196 12.688
201703 7.765 105.196 11.296
201706 7.814 107.109 11.164
201709 8.166 109.021 11.463
201712 8.921 109.404 12.479
201803 9.821 109.786 13.690
201806 9.482 111.317 13.036
201809 11.098 115.142 14.750
201812 12.911 115.142 17.160
201903 11.693 118.202 15.139
201906 12.305 120.880 15.578
201909 13.224 123.175 16.430
201912 14.476 126.235 17.549
202003 11.756 124.705 14.427
202006 14.172 127.000 17.077
202009 14.573 130.118 17.140
202012 15.423 130.889 18.032
202103 14.278 131.771 16.582
202106 14.811 134.084 16.904
202109 15.436 135.847 17.389
202112 18.128 138.161 20.080
202203 18.729 138.822 20.646
202206 17.928 142.347 19.274
202209 19.290 144.661 20.407
202212 23.992 145.763 25.189
202303 31.082 146.865 32.388
202306 28.690 150.280 29.216
202309 28.944 151.492 29.239
202312 29.626 152.924 29.647
202403 32.248 153.035 32.248

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biocon  (NSE:BIOCON) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biocon's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=305.25/66.36
=4.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biocon was 11.77. The lowest was 3.62. And the median was 7.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biocon Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biocon's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocon (NSE:BIOCON) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560 100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.

Biocon (NSE:BIOCON) Headlines

No Headlines